A Study to Assess the Efficacy and Safety of AK002 in Subjects With Antihistamine-Resistant Chronic Urticaria
Status:
Completed
Trial end date:
2020-04-06
Target enrollment:
Participant gender:
Summary
This is a Phase 2a, open-label, study to assess the effects of AK002, given as monthly
intravenous infusions at up to 3 mg/kg. A total of 47 patients will be enrolled across 2-4
sites. All patients enrolled in the study will receive 6 monthly infusions of AK002 and will
then be followed for another 8 weeks. Some patients will have the option to receive an
additional 12 months of extended dosing.